載入中
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
前收盤價
US$19.90
+US$0.77 · +4.03%
盤中時間採用ET。市場資料可能有所延遲。
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
日內區間
目前US$19.90
52週區間
目前US$19.90
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
45
合理估值
情緒
48
多空交錯
風險
72
高風險
動能
75
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
日內區間
目前US$19.90
52週區間
目前US$19.90
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | 349.2萬 USD | 896萬 USD | — |
| 毛利 | — | — | −349.2萬 USD | −896萬 USD | — |
| 研究與開發 | 3.22億 USD | 9331萬 USD | 9431.5萬 USD | 6455萬 USD | 4752.9萬 USD |
| 銷售、一般及管理費用 | 5011萬 USD | 2787.5萬 USD | 3172.1萬 USD | 1990.8萬 USD | 2148.9萬 USD |
| 營業費用 | 3.72億 USD | 1.21億 USD | 1.23億 USD | 8445.8萬 USD | 6901.8萬 USD |
| 利息收入 | 586.8萬 USD | 427.1萬 USD | 817.3萬 USD | 132.4萬 USD | 11.9萬 USD |
| 折舊和攤銷 | 288.7萬 USD | 352.8萬 USD | 349.2萬 USD | 252.5萬 USD | 143.4萬 USD |
| 營業利益 | −3.72億 USD | −1.21億 USD | −1.26億 USD | −9341.8萬 USD | −6901.8萬 USD |
| 淨利 | −6.96億 USD | −1.17億 USD | −1.18億 USD | −9209.4萬 USD | −6889.9萬 USD |
公司資料更新於 2026年10月11日。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3486.39萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2116.52萬0.21%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1937.83萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1118.15萬0.01%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO527.08萬0.03%180億 USD0.06%US$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM482.71萬0.07%64.1億 USD0.28%US$45.46+0.46%
iShares Russell 2000 Growth ETFIWO470.01萬0.03%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA396.43萬0.02%218.24億 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
